Patents by Inventor Arthur D. Riggs

Arthur D. Riggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210214692
    Abstract: Disclosed herein are methods for reprogramming a somatic cell into a pluripotent stem cell by contacting the somatic cell with one or more antifolate agents, with or without methionine, in vitro for a period of time sufficient to reprogramming the somatic cell and selecting and growing the cells that express one or more stem cell markers. Also disclosed are induced pluripotent stem cells obtained from somatic cells.
    Type: Application
    Filed: November 17, 2020
    Publication date: July 15, 2021
    Applicant: CITY OF HOPE
    Inventors: Arthur D. RIGGS, Avinash C. SRIVASTAVA, Timothy R. O'CONNOR
  • Patent number: 7923221
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: April 12, 2011
    Assignees: Genentech, Inc, City of Hope
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 7238480
    Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or near its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: July 3, 2007
    Assignee: City of Hope
    Inventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
  • Patent number: 7083926
    Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.
    Type: Grant
    Filed: May 12, 2003
    Date of Patent: August 1, 2006
    Assignee: City of Hope
    Inventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
  • Patent number: 7033763
    Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or rear its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: April 25, 2006
    Assignee: City of Hope
    Inventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
  • Publication number: 20040009515
    Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3′-deoxynucleotide at its 3′ terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3′ end for the rare allele but has a mismatch at or rear its 3′ terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3′ specific sequence as far as 16 nucleotides away from the 3′ terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.
    Type: Application
    Filed: May 9, 2003
    Publication date: January 15, 2004
    Inventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
  • Publication number: 20030228615
    Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.
    Type: Application
    Filed: May 12, 2003
    Publication date: December 11, 2003
    Inventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
  • Patent number: 6562570
    Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: May 13, 2003
    Assignee: City of Hope
    Inventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
  • Patent number: 6331415
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: December 18, 2001
    Assignee: Genentech, Inc.
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 6242567
    Abstract: Disclosed are amino acid sequences of the late 64 kilodalton protein of human cytomegalovirus (HCMVgp64), useful in diagnosing and preventing HCMV infections.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: June 5, 2001
    Assignee: City of Hope
    Inventors: Hema Pande, Arthur D. Riggs, John A. Zaia, Brian R. Clark
  • Patent number: 6133433
    Abstract: A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one (721) nucleotides. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The major late protein of human cytomegalovirus (HCMVgp64) also reacts with T-lymphocytes of an individual after natural infection of that individual with human cytomegalovirus. Thus, the HCMVgp64 protein may be used as a vaccine to prevent HCMV infection.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 17, 2000
    Assignee: City of Hope
    Inventors: Hema Pande, Arthur D. Riggs, John A. Zaia, Brian R. Clark
  • Patent number: 5583013
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: December 10, 1996
    Assignee: Genentech, Inc.
    Inventors: Keiichi Itakura, Arthur D. Riggs
  • Patent number: 5420020
    Abstract: 1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: May 30, 1995
    Assignee: Genentech, Inc.
    Inventor: Arthur D. Riggs
  • Patent number: 5270183
    Abstract: The present invention provides an apparatus and method for the amplification of a particular sequence(s) of DNA in a sample using polymerased chain reaction. The method of the present invention involves the injection of a reaction mixture into a stream of carrier fluid. The carrier fluid then passes through a plurality of temperature zones in which the polymerase chain reactions take place. The method of the present invention allows the sequential processing of a number of samples.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: December 14, 1993
    Assignee: Beckman Research Institute of the City of Hope
    Inventors: John M. Corbett, Kenneth C. Reed, Arthur D. Riggs
  • Patent number: 5221619
    Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: June 22, 1993
    Assignee: Genentech, Inc.
    Inventors: Keiichi Itakura, Arthur D. Riggs
  • Patent number: 5081235
    Abstract: A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.
    Type: Grant
    Filed: July 26, 1989
    Date of Patent: January 14, 1992
    Assignee: City of Hope
    Inventors: John E. Shively, Arthur D. Riggs, Michael Neumaier
  • Patent number: 5075213
    Abstract: A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one 721) nucleotides. The probe may be labelled as by radioactivity. The probe has been used to screen DNA fragments constituting a subgenomic library of human cytomegalovirus DNA to obtain DNA fragments coding for the major late protein of human cytomegalovirus. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The viral DNA can be used as whole HCMV DNA or as fragments formed by digesting the human cytomegalovirus DNA with a restriction endonuclease such as one of the restriction endonucleases EcoRI, BamHI, XbaI, HindIII and PrtI.
    Type: Grant
    Filed: June 20, 1990
    Date of Patent: December 24, 1991
    Assignee: City of Hope
    Inventors: Hema Pande, Arthur D. Riggs, John A. Zaia
  • Patent number: 5075431
    Abstract: A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.
    Type: Grant
    Filed: March 26, 1991
    Date of Patent: December 24, 1991
    Assignee: City of Hope
    Inventors: John E. Shively, Arthur D. Riggs, Michael Neumaier
  • Patent number: 5047320
    Abstract: A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one (721) nucleotides. The probe may be labelled as by radioactivity. The probe has been used to screen DNA fragments constituting a subgenomic library of human cytomegalovirus DNA to obtain DNA fragments coding for the major late protein of human cytomegalovirus. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The viral DNA can be used as whole HCMV DNA or as fragments formed by digesting the human cytomegalovirus DNA with a restriction endonuclease such as one of the restriction endonucleases EcoRI, BamHI, XbaI, HindIII and PrtI.
    Type: Grant
    Filed: June 20, 1990
    Date of Patent: September 10, 1991
    Assignee: City of Hope
    Inventors: Hema Pande, Arthur D. Riggs, John A. Zaia, Brian R. Clark
  • Patent number: 4816567
    Abstract: Altered and native immunoglobulins, including constant-variable region chimeras, are prepared in recombinant cell culture. The immunoglobulins contain variable regions which are immunologically capable of binding predetermined antigens. Methods are provided for refolding directly expressed immunoglobulins into immunologically active form.
    Type: Grant
    Filed: April 8, 1983
    Date of Patent: March 28, 1989
    Assignee: Genentech, Inc.
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel